This list contains core publications from each of our development programs, but it is not comprehensive. If you would like to take a deeper dive in any of our programs, please contact us.

  • , Allergy, February 2022

    "Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study"

  • , AAAAI, February 2022

    "The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria"

  • , SITC 2021, November 2021

    "CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways"

  • , EADV, September 2021

    "CDX-0159, an anti-KIT Antibody, Demonstrates Rapid and Sustained Clinical Response and Improved Quality of Life in Patients with Chronic Inducible Urticaria"

  • , EAACI, July 2021

    "The Anti-kit Antibody, CDX-0159, Reduces Disease Activity and Tryptase Levels in Patients with Chronic Inducible Urticaria"

  • , ASCO 2021 Poster, June 2021

    "A Phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies"

  • , AACR 2021 Poster, April 2021

    "Simultaneous De-repression of Innate and Adaptive Immune Responses Through Dual Targeting of ILT4 and PD-(L)1 with Bispecific Antibodies"

  • , SITC 2020 Poster, November 2020

    "CDX527-01, a Phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies"

  • , SITC 2020 Poster, November 2020

    "CDX1140-01, a Phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)"

  • , SITC 2020 Poster, November 2020

    "An Axl-targeting Monoclonal Antibody that Inhibits Axl Activity and Potently Stimulates the Innate Immune Response"

  • , EAACI, June 2020

    "CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in plasma Tryptase and a favorable safety profile in a Phase 1a healthy volunteer study"

  • , Cancer Immunology, Immunotherapy, May 2020

    "Development of CDX‑527: a bispecific antibody combining PD‑1 blockade and CD27 costimulation for cancer immunotherapy"

  • , SITC 2019 Poster, November 2019

    "Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies"

  • , SITC 2019 Poster, November 2019

    "Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers"

  • , ACAAI, November 2019

    "CDX-0159, an anti-KIT monoclonal antibody, as a modulator of mast cell-related diseases"

  • , August 2019

    "Conditioning Treatment with a CD27 Antibody Enhances in vivo Expansion and Antitumor Activity of Adoptively Transferred T Cells"

  • , AACR 2019 Presentation, April 2019

    "Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA"

  • , AACR 2019 Poster, April 2019

    "CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1"

  • , AACR 2018 Poster, April 2018

    "Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models"

  • , AACR 2019 Poster, April 2019

    "First-in-human Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results"

  • , November 2018

    "Anti-CD27 agonist antibody varlilumab in combination with nivolumab for recurrent glioblastoma: Phase 2 Clinical Trial Results"

  • , SITC 2018 Poster, November 2018

    "Preliminary results from a first-in-human phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140"

  • , AACR 2018 Presentation, April 2018

    "FLT3 Ligand (CDX-301) and Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer"

  • , AACR 2018 Poster, April 2018

    "Development of novel bispecific immune modulating antibodies"

  • , ASH 2016 Poster, December 2016

    "CDX-1140, A Novel Agonist CD40 Antibody with Potent Anti-lymphoma Activity"

  • , Society for Immunotherapy of Cancer, November 2017

    "Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy"

  • , June 2017

    "Clinical Results with Combination of Anti-CD27 Agonist Antibody, Varlilumab, with Anti-PD1 Antibody, Nivolumab, in Advanced Cancer Patients"

  • , Journal of Clinical Oncology, May 2017

    "Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors"

  • , April 2016

    "Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events"

  • , SITC 2016 Poster, November 2016

    "Functional characterization of CDX-1140, a novel CD40 antibody agonist for cancer immunotherapy"

  • , AACR 2016 Poster, April 2016

    "In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy"

  • , AACR 2016 Poster, April 2016

    "Development and characterization of novel CD40 antibody agonists for cancer immunotherapy"

  • , ASBMT 2016 Poster, February 2016

    "Preliminary Safety and Efficacy Data using CDX-301 (Flt3 ligand) as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-matched Sibling Donor Transplantation"

  • , SITC 2015 Poster, November 2015

    "The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent"

  • , Journal for ImmunoTherapy of Cancer, August 2015

    "Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab"

  • , AACR 2015 Poster, April 2015

    "Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site"

  • , Bone Marrow Transplantation, April 2015

    "Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers"

  • , SITC 2014 Poster, November 2014

    "Immune Correlates of Varlilumab (CDX-1127) Treated Cancer Patients are Consistent with CD27 Costimulatory Activity"

  • , ASCO 2014 Poster, June 2014

    "Phase I Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab [CDX-1127]) in Patients with Advanced Hematologic Malignancies"

  • , ASCO 2014 Poster, June 2014

    "Immunological Activity of an Activating Anti-CD27 Antibody (Varlilumab [CDX-1127]) in Patients with Solid Tumors"

  • , OncoImmunology, January 2014

    "Targeting human CD27 with an agonist antibody stimulates T cell activation and antitumor immunity"

  • , SITC 2013 Poster, November 2013

    "Combination Therapies Augment the Anti-Tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models"

  • , SITC 2013 Poster, November 2013

    "A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors"

  • , SITC 2013 Poster, November 2013

    "A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors"

  • , Journal of Immunology, September 2013

    "Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27 Transgenic Mice"

  • , AACR 2013 Poster, April 2013

    "Characterization of the Response of Human T cells to an Agonistic Anti-CD27 mAb"

  • , BMT 2013 Presentation, February 2013

    "A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers"

  • , ASH 2012 Poster, December 2012

    "A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers"

  • , Clinical Cancer Research, May 2012

    "Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia"

  • , AACR 2012 Poster, April 2012

    "Appropriate cross-linking is required for co-stimulatory activity of human anti-CD27 antibody in a transgenic mouse model"

  • , ASH 2011 Poster, December 2011

    "Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms"

  • , AACR 2011 Poster, April 2011

    "Anti-tumor Activity of a Fully Human anti-CD27 Monoclonal Antibody in a Transgenic Mouse Model"

  • , AACR 2010 Poster, April 2010

    "Development of Novel Anti-CD27 Human Antibodies with Therapeutic Potential"

Load More